Zoetis (ZTS) Stock Price, News & Analysis

Company Overview

Zoetis Inc. is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health. The company serves customers in markets around the world through its commercial, manufacturing and research operations. Kristin Peck has served as Zoetis' chief executive officer since 2020.

Key Stats

• Today's Range: $69.52 to $70.77
• 50-Day Range: $69.76 to $77.89
• 52-Week Range: $69.52 to $148.79
• Volume: 4.43 million shs
• Average Volume: 4.32 million shs
• Market Capitalization: $28.83 billion
• P/E Ratio: 11.49
• Dividend Yield: 3.04%
• Price Target: $101.08
• Consensus Rating: Hold

Zoetis Stock Analysis - MarketRank™

Zoetis scored higher than 96% of companies evaluated by MarketBeat, and ranked 7th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Zoetis has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on no strong buy ratings, 8 buy ratings, 9 hold ratings, and 2 sell ratings.

Upside Potential

Zoetis has a consensus price target of $101.08, representing about 44.9% upside from its current price of $69.76.

Amount of Analyst Coverage

Zoetis has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 2.10%

Earnings Growth

Earnings for Zoetis are expected to grow by 2.10% in the coming year, from $6.20 to $6.33 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zoetis is 11.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zoetis is 11.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.68.

Price to Earnings Growth Ratio

Zoetis has a PEG Ratio of 1.64. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zoetis has a P/B Ratio of 9.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.22% of the float of Zoetis has been sold short.

Short Interest Ratio / Days to Cover

Zoetis has a short interest ratio ("days to cover") of 3.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zoetis has recently decreased by 10.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Zoetis pays a meaningful dividend of 3.02%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zoetis has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Zoetis is 34.93%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zoetis will have a dividend payout ratio of 33.49% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.27

News Sentiment

Zoetis has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Zoetis this week, compared to 8 articles on an average week.

Search Interest

Only 20 people have searched for ZTS on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.

MarketBeat Follows

11 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zoetis insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.22% of the stock of Zoetis is held by insiders.

Percentage Held by Institutions

92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 9/1 Dividend: 7/20/2026
• Ex-Dividend for 9/1 Dividend: 7/20/2026
• Last Earnings: 8/06/2026
• Dividend Payable: 9/01/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ZTS
• CIK: 1555280
• Web: www.zoetis.com
• Phone: (973) 822-7000
• Fax: 302-655-5049
• Employees: 14,500
• Year Founded: 1952

Price Target and Rating

• Average Price Target for Zoetis: $101.08
• High Price Target: $160.00
• Low Price Target: $80.00
• Potential Upside/Downside: +44.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.32
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.07
• Trailing P/E Ratio: 11.49
• Forward P/E Ratio: 11.25
• P/E Growth: 1.64
• Net Income: $2.67 billion
• Net Margins: 27.49%
• Pretax Margin: 34.66%
• Return on Equity: 74.89%
• Return on Assets: 18.59%

Debt

• Debt-to-Equity Ratio: 2.87
• Current Ratio: 3.08
• Quick Ratio: 1.84

Sales & Book Value

• Annual Sales: $9.47 billion
• Price / Sales: 3.05
• Cash Flow: $7.51 per share
• Price / Cash Flow: 9.29
• Book Value: $7.56 per share
• Price / Book: 9.23

Miscellaneous

• Outstanding Shares: 413,220,000
• Free Float: 412,315,000
• Market Cap: $28.83 billion
• Optionable: Optionable
• Beta: 0.73